The ‘ideal' Nevolat® patient
Nevolat® can benefit adults and adolescents striving to manage their weight in addition to a reduced calorie diet and increased physical activity.*
Nevolat® can benefit adults and adolescents striving to manage their weight in addition to a reduced calorie diet and increased physical activity.*
It could benefit your patients who:
Are considered obese according to their BMI (≥30 kg/m²)¹
Are considered overweight according to their BMI (≥27 kg/m²) with at least one other weight-related comorbidity**¹
Would benefit from the weight-loss focus afforded by a daily dosing regimen (to support regular daily dietary and activity targets)
Are looking for a long-term and sustainable weight management therapy¹
*Treatment with Nevolat should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.
**Such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.
BMI, Body Mass Index; GLP-1 RA, glucagon-like peptide-1 receptor agonist; SmPC, Summary of Product Characteristics.
- Nevolat® (liraglutide) Summary of Product Characteristics.
000697587 | December 2024